The S&P/ASX 200 Index (ASX: XJO) is out of form and dropping into the red. In afternoon trade, the benchmark index is down 0.5% to 8,926.5 points.
Four ASX shares that are not letting that hold them back are listed below. Here's why they are rising:
Image source: Getty Images
Australian Clinical Labs Ltd (ASX: ACL)
The Australian Clinical Labs share price is up 9% to $2.73. Investors have been buying this pathology services provider's shares following the release of its full year results. It posted a 6.4% increase in total revenue to $741.3 million and 7.7% lift in underlying net profit after tax to $34 million. Australian Clinical Labs CEO Melinda McGrath said: "Despite a challenging external environment, which saw slower market growth in the second half of FY 2025, the second half performance delivered our earnings guidance."
Coles Group Ltd (ASX: COL)
The Coles Group share price is up over 8% to $22.49. This follows the release of the supermarket giant's FY 2025 results. Coles reported a 3.6% increase in group sales to $44,352 million and an 10.7% jump in normalised underlying EBITDA to $4,052 million. Management also revealed that FY 2026 has started strongly with supermarkets sales revenue increasing by 4.9% (7.0% ex-tobacco) during the first eight weeks. This is being "supported by continued strength in volumes as we continue to invest in customer value and experience."
Kelsian Group Ltd (ASX: KLS)
The Kelsian Group share price is up 15% to $4.64. This has been driven by the travel and transport company's full year results. The Sealink owner revealed a 9.5% increase in revenue to $2,208.9 million and a 7.4% lift in underlying EBITDA to $285 million. Looking ahead, management expects FY 2026 underlying EBITDA to be between $297 million and $310 million. This represents growth of 4.2% to 8.8%. Kelsian CEO, Graeme Legh, said: "We have a clearly defined capital management strategy, a clear plan for the potential divestment of our Tourism Portfolio, and a disciplined growth focus. Supported by a strengthened balance sheet, I am confident in our ability to deliver sustainable long term shareholder value."
Nanosonics Ltd (ASX: NAN)
The Nanosonics share price is up 12% to $4.62. This morning, this infection prevention company released its FY 2025 results and posted a 17% increase in total revenue to $198.6 million and a 72% jump in profit before tax to $22.3 million. Nanosonics CEO, Michael Kavanagh, said: "FY25 reflects a strong financial performance and a year in which we continued to lay the foundations for our next growth horizon. Our business model continues to demonstrate its strength and scalability. With a large cumulative installed base of 37,000 units, up 6% year-on-year, we are seeing this foundation translate into significant recurring revenue growth."
